84 Chinese patients with prostate cancer treated with SRT to the prostatic fossa alone during 2006-2017 at Tuen Mun Hospital, Hong Kong
Results: Median SRT dose given was 70 Gy (range, 64-76 Gy).
Median pre-SRT PSA level was 0.4 ng/mL (0.2-7.4 ng/mL).
After SRT, 47 (56%) patients had undetectable (<0.1 ng/mL) PSA levels. [Mine were undetectable for 4 months]
After median follow-up of 48 months (2 months to 10 years),
25 (30%) patients had further biochemical progression.
Subsequently, 12 patients received androgen deprivation therapy and
9 (11%) developed distant metastasis.
The 5-year biochemical progression-free survival, androgen deprivation therapy-free survival and metastasis-free survival were
62.7%, BPFS
83.5% ADT free survival and
86.7% metastisis free survival, respectively.
Lower BPFS (biochemical progression free survival) after sRT was associated with;
PSA failure after radical prostatectomy (hazard ratio 7.4),
negative surgical margin (hazard ratio 2.7),
positive extracapsular extension (hazard ratio 4.6),
and detectable PSA levels after SRT (hazard ratio 17.3)
Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy - PubMed (nih.gov)
